Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML)

Jay Yang, MD, Farhad Ravandi, MD, Anjali Advani, MD, Sumithira Vasu, MBBS, Roland B. Walter, MD PhD, Stefan Faderl, MD, Anthony S. Stein, MD, Harry P. Erba, MD PhD, Amir T. Fathi, MD, William B. Donnellan, MD, Moshe Y Levy, MD, Scott E. Smith, MD PhD, Brent L. Wood, MD PhD, Eric J. Feldman, MD, Jenna L Voellinger, PhD, Michael B. Maris, MD

Blood (2016) 128 (22): 340.

https://doi.org/10.1182/blood.V128.22.340.340

Published: 2016

Journal Articles

Cytomegalovirus Reactivation Does Not Increase Subsequent Risk for Acute Graft-Versus-Host Disease, Malignant Disease Relapse, or Infection Following Allogeneic Hematopoietic Cell Transplantation

Blood (2016) 128 (22): 3409.

https://doi.org/10.1182/blood.V128.22.3409.3409

Published: 2016

Journal Articles

Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation

Blood (2016) 128 (22): 3410.

https://doi.org/10.1182/blood.V128.22.3410.3410

Published: 2016

Journal Articles

Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naveen Pemmaraju, MD, Andrew A. Lane, MD PhD, Kendra L. Sweet, MD, Anthony S. Stein, MD, Sumithira Vasu, MBBS, William Blum, MD, David A Rizzieri, MD, Eunice S. Wang, MD, Madeleine Duvic, MD, Janice Chen, PhD, Shay Shemesh, MA, Peter McDonald, Christopher L. Brooks, PhD, Jeffrey E. Lancet, MD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 342.

https://doi.org/10.1182/blood.V128.22.342.342

Published: 2016

Journal Articles

A Novel Regimen for Acute Myeloid Leukemia with MLL Partial Tandem Duplication: Results of a Phase 1 Study NCI 8485

Alice S. Mims, MD MSCR, Rebecca B Klisovic, MD, Ramiro Garzon, MD, Alison R. Walker, MD MPH, Steven M. Devine, MD, Katherine J. Walsh, MD, Sumithira Vasu, MBBS, Susan P. Whitman, PhD, Guido Marcucci, MD, Nyla A. Heerema, PhD, Michael A. Caligiuri, MD, Clara D. Bloomfield, MD, John C. Byrd, MD, Richard Piekarz, PhD MD, Michael R. Grever, MD, William Blum, MD

Blood (2016) 128 (22): 900.

https://doi.org/10.1182/blood.V128.22.900.900

Published: 2016

Journal Articles

CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia

Swagata Goswami, MS, Rajeswaran Mani, DVM PhD, Chi-Ling Chiang, MS, Frank W Frissora, M.S., Xiaokui Mo, PhD MAS, Zhiliang Xie, Donna Bucci, Amber Gordon, MLS, David M. Lucas, PhD, William Blum, MD, Alison R. Walker, MD MPH, Alice S. Mims, MD MSCR, Rebecca B Klisovic, MD, Ching-Shih Chen, PhD, Robert J Lee, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Sumithira Vasu, MBBS, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 2748.

https://doi.org/10.1182/blood.V128.22.2748.2748

Published: 2016

Journal Articles

A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Harry P. Erba, MD PhD, Moshe Y Levy, MD, Sumithira Vasu, MBBS, Anthony S. Stein, MD, Amir T. Fathi, MD, Michael B. Maris, MD, Anjali Advani, MD, Stefan Faderl, MD, Scott E. Smith, MD PhD, Brent L. Wood, MD PhD, Roland B. Walter, MD PhD, Jay Yang, MD, William B. Donnellan, MD, Eric J. Feldman, MD, Jenna L Voellinger, PhD, Farhad Ravandi, MD

Blood (2016) 128 (22): 211.

https://doi.org/10.1182/blood.V128.22.211.211

Published: 2016

Journal Articles

Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)

Hassan Issa, MD, Amy S. Ruppert, MAS, Patrick Elder, M.S, Craig Hofmeister, Don M Benson, MD PhD, Sam Penza, MD, Leslie A. Andritsos, MD, Rebecca B. Klisovic, MD, Sumithira Vasu, MBBS, William Blum, MD, Samantha M. Jaglowski, MD, Steven M. Devine, MD, Yvonne A Efebera, MD

Blood (2015) 126 (23): 4328.

https://doi.org/10.1182/blood.V126.23.4328.4328

Published: 2015

Journal Articles

In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease

Shaneice Mitchell, BS, Shelley Orwick, BS, Matthew Cannon, BS, Virginia M. Goettl, DVM , PhD, Taylor D. LaFollette, Erkan Baloglu, PhD, William Senapedis, PhD, Alison R. Walker, MD, Bhavana Bhatnagar, Alice S. Mims, MD, Rebecca B. Klisovic, MD, Sumithira Vasu, MBBS, William Blum, MD, David M. Lucas, PhD, James S. Blachly, MD, Ramiro Garzon, MD, Clara D. Bloomfield, MD, Rosa Lapalombella, PhD, John C. Byrd, MD

Blood (2015) 126 (23): 2471.

https://doi.org/10.1182/blood.V126.23.2471.2471

Published: 2015

Journal Articles

Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)

Kendra L. Sweet, MD, Naveen Pemmaraju, MD, Andrew A Lane, MD PhD, Anthony S. Stein, MD, Sumithira Vasu, MBBS, William Blum, MD, David A. Rizzieri, MD, Eunice S. Wang, MD, Eric K. Rowinsky, MD, Michael Szarek, PhD, Christopher L. Brooks, PhD, Sarah Disalvatore, MPH, David Liu, Madeleine Duvic, MD, Jonathan D. Schwartz, MD, Marina Konopleva, MD PhD

Blood (2015) 126 (23): 3795.

https://doi.org/10.1182/blood.V126.23.3795.3795

Published: 2015

Journal Articles

Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation

Sumithira Vasu, MBBS, Anissa Bingman, M.S., Susan Geyer, PhD, Patrick Elder, Rhonda Kitzler, BS, Hillary Bradbury, Lynn Odonnell, William Blum, MD, Samantha M. Jaglowski, MD MPH, Leslie A. Andritsos, MD, Rebecca B. Klisovic, MD, Sam Penza, MD, Yvonne A Efebera, MD, Craig C. Hofmeister, MD, Don M. Benson, MD PhD, Natarajan Muthusamy, DVM, PhD, Gerard Lozanski, MD, Steven M. Devine, MD

Blood (2014) 124 (21): 2494.

https://doi.org/10.1182/blood.V124.21.2494.2494

Published: 2014

Journal Articles

Impact of Atorvastatin on Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

Yvonne A Efebera, MD, Susan Geyer, PhD, Anissa Bingman, M.S., Rhonda Kitzler, BS, Patrick Elder, MS, Leslie A. Andritsos, MD, Samantha M. Jaglowski, MD MPH, Sumithira Vasu, MBBS, William Blum, MD, Rebecca B. Klisovic, MD, Sam Penza, MD, Kevin Coombes, PhD, Craig C Hofmeister, MD MPH, Don Benson, MD PhD, Steven M. Devine, MD, Gerard Lozanski, MD

Blood (2014) 124 (21): 1166.

https://doi.org/10.1182/blood.V124.21.1166.1166

Published: 2014

Journal Articles

A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies

Bradley M. Haverkos, MD MPH, Katie Cortright, BS, Leslie A. Andritsos, MD, William Blum, MD, Rebecca B. Klisovic, MD, Sumithira Vasu, MBBS, David M Goldenberg, ScD, MD, William A Wegener, MD PhD, Steven M. Devine, MD, Samantha M. Jaglowski, MD MPH

Blood (2014) 124 (21): 1168.

https://doi.org/10.1182/blood.V124.21.1168.1168

Published: 2014

Journal Articles

A Phase I Dose Escalation Study of Lenalidomide Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

Leslie A. Andritsos, MD, William Blum, MD, Rebecca B. Klisovic, MD, Sumithira Vasu, MBBS, Sam Penza, MD, Jodi Lee, RN, Guido Marcucci, MD, John C. Byrd, MD, Steven M. Devine, MD

Blood (2014) 124 (21): 3954.

https://doi.org/10.1182/blood.V124.21.3954.3954

Published: 2014

Journal Articles

Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT)

Yvonne A Efebera, MD, Susan Geyer, PhD, Anissa Bingman, M.S., Patrick Elder, MS, Rhonda Kitzler, BS, Kevin Coombes, PhD, Carrie Hennelly, MA, Katie Cortright, BS, Leslie A. Andritsos, MD, Samantha M. Jaglowski, MD MPH, Sumithira Vasu, MBBS, William Blum, MD, Rebecca B. Klisovic, MD, Sam Penza, MD, Craig C Hofmeister, MD MPH, Don M Benson, MD PhD, Gerard Lozanski, MD, Steven M. Devine, MD

Blood (2014) 124 (21): 3929.

https://doi.org/10.1182/blood.V124.21.3929.3929

Published: 2014

Journal Articles

An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Arthur E. Frankel, MD, Jung H. Woo, PhD, Jeremy P. Mauldin, PhD, Hetty E. Carraway, MD, MBA, Olga Frankfurt, MD, Stephen J. Forman, MD, Sumithira Vasu, MBBS, Naveen Pemmaraju, MD, Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, FRCPC, Francine Garanache-Ottou, Ph.D., Fanny Angelot-Delettre, PhD, Christopher Brooks, PhD, Michael Szarek, PhD, Ivan Bergstein, MD, Eric Rowinsky, MD

Blood (2013) 122 (21): 2682.

https://doi.org/10.1182/blood.V122.21.2682.2682

Published: 2013

Journal Articles

FLT3L and AMD3100 Combination Increases Hematopoietic Stem Cell Mobilization and Leads To Improved Transplantation Outcome

Shun He, PhD, Deng Youcai, MS, Sumithira Vasu, MBBS, Jianhong Chu, Shunzong Yuan, Jianying Zhang, Zhijin Fan, Craig C Hofmeister, MD, Xiaoming He, Henry March, Steven M. Devine, MD, Jianhua Yu, PhD

Blood (2013) 122 (21): 901.

https://doi.org/10.1182/blood.V122.21.901.901

Published: 2013

Journal Articles

Decitabine Or 5-Azacitidine Pre-Treatment Does Not Compromise The Novel Fc-Engineered Antibody Mab 33.1-Mediated ADCC Against Primary AML Blasts - A Rationale For Combination Therapy

Shun He, PhD, Carolyn Cheney, Susan P. Whitman, PhD, Jianhua Yu, PhD, Sumithira Vasu, MBBS, William Blum, MD, Karl-Heinz Heider, PhD, Guido Marcucci, MD, Natarajan Muthusamy, DVM, Ph.D

Blood (2013) 122 (21): 3959.

https://doi.org/10.1182/blood.V122.21.3959.3959

Published: 2013

Journal Articles

Phase I Study Of The Combination Of Midostaurin, Bortezomib and Chemotherapy In Relapsed/Refractory Acute Myeloid Leukemia (AML): Targeting Aberrant Tyrosine Kinase Activity

Alison R Walker, MD, Hongyan Wang, PhD, Rebecca Klisovic, MD, Katherine Walsh, MD, Sumithira Vasu, MBBS, Ramiro Garzon, MD, Steven M. Devine, MD, Amy Drake, William Blum, MD, Guido Marcucci, MD

Blood (2013) 122 (21): 3966.

https://doi.org/10.1182/blood.V122.21.3966.3966

Published: 2013

Journal Articles

Micrornas Promote Activation and Maturation of Natural Killer Cells Through Toll-Like Receptor Signaling.

Jianhua Yu, PhD, Shun He, Lai-Chu Wu, PhD, Hsiaoyin Mao, Sumithira Vasu, MBBS, Samantha M. Jaglowski, MD, MPH, Yong Peng, Christopher Alvarez-Breckenridge, Shunzong Yuan, Ph.D., M.D., Min Wei, Jianying Zhang, Tiffany L Hughes, Kalpana Ghoshal, Steven M. Devine, MD, Michael A. Caligiuri, M.D.

Blood (2012) 120 (21): 2160.

https://doi.org/10.1182/blood.V120.21.2160.2160

Published: 2012

NARROW

A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML)

Cytomegalovirus Reactivation Does Not Increase Subsequent Risk for Acute Graft-Versus-Host Disease, Malignant Disease Relapse, or Infection Following Allogeneic Hematopoietic Cell Transplantation

Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation

Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

A Novel Regimen for Acute Myeloid Leukemia with MLL Partial Tandem Duplication: Results of a Phase 1 Study NCI 8485

CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia

A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)

In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease

Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)

Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation

Impact of Atorvastatin on Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies

A Phase I Dose Escalation Study of Lenalidomide Following Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation

Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT)

An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

FLT3L and AMD3100 Combination Increases Hematopoietic Stem Cell Mobilization and Leads To Improved Transplantation Outcome

Decitabine Or 5-Azacitidine Pre-Treatment Does Not Compromise The Novel Fc-Engineered Antibody Mab 33.1-Mediated ADCC Against Primary AML Blasts - A Rationale For Combination Therapy

Phase I Study Of The Combination Of Midostaurin, Bortezomib and Chemotherapy In Relapsed/Refractory Acute Myeloid Leukemia (AML): Targeting Aberrant Tyrosine Kinase Activity

Micrornas Promote Activation and Maturation of Natural Killer Cells Through Toll-Like Receptor Signaling.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only